JAK2 and myeloproliferative disorder: Here, treatment with tamoxifen in Janus Kinase 2 (JAK2) V617F mutation-induced MPN caused a significant reduction in disease development and eliminated all of the commonly associated phenotypes of the disease including erythrocytosis, thrombocytosis and leukocytosis [29].